Seagen, a wholly owned subsidiary of Pfizer
Clinical trials sponsored by Seagen, a wholly owned subsidiary of Pfizer, explained in plain language.
Biotech company developing antibody-drug conjugates for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo shows promise for tough bladder cancer Results expected Dec 2026 (estimated)
- New drug combo aims to outdo chemo for advanced bladder cancer Results expected Jan 2027 (estimated)
- New cancer drug sigvotatug vedotin enters human trials Results expected Jun 2027 (estimated)
- New drug combo targets tough blood cancers in early trial Results expected Jul 2027 (estimated)
-
New hope for advanced cervical cancer: targeted drug combo shows promise
Disease control Stopped earlyThis trial tested a drug called tisotumab vedotin, alone or with other medicines, in people with cervical cancer that had come back or spread. The study included 214 participants and aimed to find the best dose and see if the tumors shrank. The trial was stopped early, but the re…
Phase 1/2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Experimental cancer drug tested in early trial, but study stopped early
Disease control Stopped earlyThis early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New lymphoma drug trial halted early
Disease control Stopped earlyThis early-stage study tested a new drug, PF-08046044/SGN-35C, in people with advanced lymphomas (Hodgkin and non-Hodgkin types) who had no other treatment options. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New lymphoma drug trial halted early
Disease control Stopped earlyThis study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug trial offers hope for Hard-to-Treat cancers
Disease control Stopped earlyThis early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC